Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Amado RG, Wolf M, Peeters M, Van Cutsem E, et al. J Clin Oncol 2023;41:3278-3286.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Amado RG, Wolf M, Peeters M, Van Cutsem E, et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2023;41:3278-3286.
PMID: 37315390